Cargando…

Clinical evaluation of zaleplon in the treatment of insomnia

Zaleplon is a pyrazolopyrimidine hypnotic used for the treatment of insomnia. Zaleplon binds preferentially at the α1β2γ2 subunit of gamma aminobutyric acid type A (GABA(A)) receptors in the central nervous system, and has a half-life of about one hour. Efficacy studies show that zaleplon is a suita...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebbens, Marieke M, Verster, Joris C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3630939/
https://www.ncbi.nlm.nih.gov/pubmed/23616704
_version_ 1782266731197104128
author Ebbens, Marieke M
Verster, Joris C
author_facet Ebbens, Marieke M
Verster, Joris C
author_sort Ebbens, Marieke M
collection PubMed
description Zaleplon is a pyrazolopyrimidine hypnotic used for the treatment of insomnia. Zaleplon binds preferentially at the α1β2γ2 subunit of gamma aminobutyric acid type A (GABA(A)) receptors in the central nervous system, and has a half-life of about one hour. Efficacy studies show that zaleplon is a suitable hypnotic for sleep initiation purposes. However, because of its short half-life, zaleplon is less effective in sleep maintenance when compared with other hypnotics. Nevertheless, zaleplon does increase total sleep time. No rebound effects are observed after treatment discontinuation. The use of zaleplon is relatively safe. Adverse effects are mild and of short duration. No important interactions have been reported, and there is no evidence of abuse potential. Relative to benzodiazepine hypnotics, the biggest advantage of zaleplon is that current evidence suggests it does not produce residual next-day effects. As early as four hours after intake of zaleplon, no effects on cognitive, memory, psychomotor performance, and the ability to drive a car have been reported. Future studies should confirm these findings, and comparisons with new nonbenzodiazepine hypnotics should determine the importance of zaleplon in the future treatment of insomnia.
format Online
Article
Text
id pubmed-3630939
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-36309392013-04-24 Clinical evaluation of zaleplon in the treatment of insomnia Ebbens, Marieke M Verster, Joris C Nat Sci Sleep Review Zaleplon is a pyrazolopyrimidine hypnotic used for the treatment of insomnia. Zaleplon binds preferentially at the α1β2γ2 subunit of gamma aminobutyric acid type A (GABA(A)) receptors in the central nervous system, and has a half-life of about one hour. Efficacy studies show that zaleplon is a suitable hypnotic for sleep initiation purposes. However, because of its short half-life, zaleplon is less effective in sleep maintenance when compared with other hypnotics. Nevertheless, zaleplon does increase total sleep time. No rebound effects are observed after treatment discontinuation. The use of zaleplon is relatively safe. Adverse effects are mild and of short duration. No important interactions have been reported, and there is no evidence of abuse potential. Relative to benzodiazepine hypnotics, the biggest advantage of zaleplon is that current evidence suggests it does not produce residual next-day effects. As early as four hours after intake of zaleplon, no effects on cognitive, memory, psychomotor performance, and the ability to drive a car have been reported. Future studies should confirm these findings, and comparisons with new nonbenzodiazepine hypnotics should determine the importance of zaleplon in the future treatment of insomnia. Dove Medical Press 2010-07-20 /pmc/articles/PMC3630939/ /pubmed/23616704 Text en © 2010 Ebbens and Verster, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Ebbens, Marieke M
Verster, Joris C
Clinical evaluation of zaleplon in the treatment of insomnia
title Clinical evaluation of zaleplon in the treatment of insomnia
title_full Clinical evaluation of zaleplon in the treatment of insomnia
title_fullStr Clinical evaluation of zaleplon in the treatment of insomnia
title_full_unstemmed Clinical evaluation of zaleplon in the treatment of insomnia
title_short Clinical evaluation of zaleplon in the treatment of insomnia
title_sort clinical evaluation of zaleplon in the treatment of insomnia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3630939/
https://www.ncbi.nlm.nih.gov/pubmed/23616704
work_keys_str_mv AT ebbensmariekem clinicalevaluationofzaleploninthetreatmentofinsomnia
AT versterjorisc clinicalevaluationofzaleploninthetreatmentofinsomnia